Bryan Bass

Senior Genomic Specialist with Decipher Biosciences- learning about Urologic Oncology through Twitter.

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#5001 @ASCO #ASCO26 by @ChrisSweens1👉 https://t.co/u08U4HEinq👉Decipher Prostate Genomic Classifier (DGC) predicts benefit w/ triplet Rx in #prostatecancer👉DGC>0.85 is predictive of benefit from adding docetaxel to ADT+Enza👇@Prof_IanD @OncoAlert @urotoday @PCF_science

[Adam B. Weiner, MD @Adam_Weiner535]

🧬 Active surveillance (AS) ≠ one-size-fits-all for #ProstateCancer

🚨 New @EurUrolOncol data on Genomic Classifier (GC) in AS:

🔺High GC (≥0.6) → ↑ risk of major upgrading (GG≥3)
🔬↑ risk of unfavorable histology (IDC / cribriform)
🎯👀 Signals who may need closer surveillance, not overtreatment

🧠Risk-adapted AS matters

🔗https://t.co/ys2QaELgO8

@dr_coops @KShee11 @Decipher_VCYT @Davicioni @PCFnews @UrologyTimes @renalandurology @MRoupret

[RadOncUH @RadOncUH]

@DrSpratticus presenting @NRGonc the 1st prospectively validated biomarker 🧬—PAM50—in post-op salvage RT ☢️
🔹 Luminal B (biomarker ➕): HR 0.27 for MFS benefit w/ apalutamide
🔹 Non-Luminal B (biomarker ➖): HR 1.06

Precision medicine in action #PCSM

[Bryan Bass @kingowing]

@toddarcher Derek Rose

[Thomas Zilli @ZilliThomas]

⁦@APCCC_Lugano⁩ ⁦@dr_coops⁩

[Elai Davicioni @Davicioni]

https://t.co/Yl5yV6BcHi via @urotoday @DrSpratticus @zklaassen_md great presentation and discussion- the future looks bright!

[UroToday.com @urotoday]

Decipher score as a predictor of response to treatment intensification in the @NRGOncology-RTOG 0534 #SPPORT phase III randomized post-prostatectomy salvage radiotherapy trial. Presentation by @_APollack @SylvesterCancer. #GU25 written coverage by @RKSayyid @USC > https://t.co/kfbwmOsNzq @Decipher_VCYT

[Zach Klaassen @zklaassen_md]

Decipher risk strat of radiorecurrent PCa: Correlative analysis of the F-SHARP trial of salvage re-RT @abhiAsolanki @urotoday #GU25

☑️Higher Decipher score:
- ⬆️risk of bPFS: HR 1.70, 95%1.05-2.75
- ⬆️risk of LRFS: HR 2.30, 95%CI 1.02-5.18
- ⬆️risk of rPFS: HR 2.47, 95%CI 1.23.-4.97

☑️Decipher high vs lower risk @ 3 yrs:
- bPFS: 43% vs 75%
- LRFS: 58% vs 100%
- rPFS: 42% vs 100%

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

Decipher @Decipher_VCYT proving to be a strong signature in Adv prostate cancer #ESMO24

Great work exploring a range of signatures on the #STAMPEDE trial @AttardLab @Prof_Nick_James @Davicioni

Looking forward to the publication!

#ESMOAmbassadors

[Urology Times @UrologyTimes]

The Decipher prostate test has received a Level 1B evidence rating, the highest rating among molecular tests, in the 2024 NCCN Clinical Practice Guidelines in Oncology. #pcsm #urology

Read more: https://t.co/GGOrkT4iqp

[Veracyte, Inc. @Veracyte]

Veracyte today announced that it’s Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 @NCCN Guidelines® as a prognostic tool for the risk stratification of patients with localized #ProstateCancer.

[𝗙𝗮𝗿𝘀𝗵𝗮𝗱 @farshadsarrafi]

Unpopular Opinion:

“Discipline” is not the reason why people are successful.

Successful people understand what their behaviors, repeated over time and practice, will facilitate.

[Daniel E Spratt @DrSpratticus]

@angela_jia_ giving a podium talk @ASTRO_org #ASTRO23 and absolutely crushing it.

The gene expression used in the 3 most common PCa tests in 50,000 pts do not correlate, with ~60% of data being unique in Decipher as compared to derived CCP or GPS.

Clearly these tests are not interchangeable in the info provided.

#radonc #PCSM @urotoday @PCFnews @RadOncUH

[UroToday.com @urotoday]

Cross-comparison individual patient-level analysis of three gene expression signatures in localized prostate in over 50,000 men. Presentation by @angela_jia_ @RadOncUH. #ASTRO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/vmumPPxApP @ASTRO_org

[Tommy Schultz 🇺🇸 @Tommy_USA]

Our education system needs more of this:

“Truth is good for kids. We’re so busy lying we don’t recognize truth anymore”.

[UroToday.com @urotoday]

Risk assessment in localized #ProstateCancer - Insights from real-world data and SEER registry. @jimhumd @WeillCornell joins @ashleyrossmdphd @NM_Urology to discuss the use of genomic classifiers in the mgmt of localized PCa on UroToday > https://t.co/0qXTiUwC1m @Decipher_VCYT

[UroToday.com @urotoday]

Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT

[UroToday.com @urotoday]

Active surveillance: Optimizing the quality of life in men with localized #ProstateCancer. @dr_sprenkle @Yale_Urology & @randy_vincejr @CaseUrology join @ashleyrossmdphd @NUFeinbergMed to discuss on UroToday > https://t.co/HKEzjjSNTl @MUSICUrology @Decipher_VCYT

[Rashid K. Sayyid @RKSayyid]

SEER-Decipher data of 100K men w/ GG1-2 PCa (Decipher: 2.9K) w/ Decipher test at init bx:
🚩Decipher testing assoc w/ ⬆️ odds of conserv mngmt (OR: 2.1,p<0.001)
🚩Men treated w/ RP: ⬆️ GC score associated w/ adverse path (GG3/pT3b/pN+): OR 1.25 per 0.1 score ⬆️
@urotoday #AUA23

[Decipher by Veracyte @Decipher_VCYT]

Veracyte's Decipher team is in Chicago, exhibiting at the American Urological Associations 2023 (#AUA23) meeting taking place April 28 - May 1! If you're attending, visit booth #637 to hear about some of our latest research efforts to help patients with #ProstateCancer.